Drug Trial Radar · NCT00538785
A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
Last checked: Nov 20, 2026Latest source record: Feb 16, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,236
Actual
Start
Oct 2005
Primary completion
Jun 2008
Study completion Jun 2008
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 3, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, up to 24 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary goal was to describe the safety of the investigational product when given monthly to prevent serious respiratory infection among children with significant heart disease.
Conditions
- Congenital Heart Disease
Interventions
MotavizumabBiological
15 mg/kg IM administered at monthly intervals
PalivizumabBiological
15 mg/kg IM administered at monthly intervals
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Reporting Adverse Events Through Study Day 150Time frame: Days 0-150
- Number of Subjects Reporting Serious Adverse Events Through Study Day 150Time frame: Days 0-150
- Number of Subjects Reporting Laboratory Adverse EventsTime frame: Days 0-150
Locations
152 sites in 17 countries. Site status is shown where the registry gives one.
Arkansas Pediatric Clinic
Little Rock, Arkansas
Miller Children's Hospital
Long Beach, California
Childrens Hospital Los Angeles
Los Angeles, California
Children's Hospital and Research Center at Oakland
Oakland, California
University of California Davis Medical Center
Sacramento, California
Children's Hospital And Health Center
San Diego, California
Yale New Haven Children's Hospital
New Haven, Connecticut
Children's National Medical Center
Washington D.C., District of Columbia
Nemours Children's Clinic Biomedical Research Department
Orlando, Florida
James Whitcomb Riley Hospital for Children
Indianapolis, Indiana
Memorial Hospital of South Bend
South Bend, Indiana
Tulane University Health Sciences Center
New Orleans, Louisiana
University of Maryland
Baltimore, Maryland
Johns Hopkins Hospital
Baltimore, Maryland
Tufts - New England Medical Center
Boston, Massachusetts
Children's Hospital Boston
Boston, Massachusetts
Children's Hospital of Michigan
Detroit, Michigan
Mayo Clinic
Rochester, Minnesota
Children's Mercy Hospital
Kansas City, Missouri
Washington University School of Medicine
St Louis, Missouri
University of Rochester
Rochester, New York
Suny At Stony Brook University Medical Center
Stony Brook, New York
Univ. of North Carolina
Chapel Hill, North Carolina
Akron Children's Hospital
Akron, Ohio
Children's Hospital of Oklahoma
Oklahoma City, Oklahoma
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Children's Cardiology Associates PLLC
Austin, Texas
Texas Children's Hospital
Houston, Texas
University of Virginia
Charlottesville, Virginia
Universitätsklinik für Kinder- und Jugendheilkunde
Innsbruck, Austria
Allgemeines Krankenhaus Linz
Linz, Austria
Universitätsklinik für Kinder- und Jugendheilkunde
Wein, Austria
Ziekenhuisnetwerk Antwerpen - Koningin Paola Kinderziekenhuis
Antwerp, Belgium
UZ Brussel
Brussells, Belgium
Hôpital Universitaire des Enfants Reine
Brussels, Belgium
UZ Brussel
Brussels, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
UZ Antwerpen
Edegem, Belgium
UZ Gent
Ghent, Belgium
Showing 40 of 152 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.